Agustin Lopez Marquez
Agustin recently served as Head of the Innovation and Advanced Analytics team and Head of Market Intelligence and Insights for the Global Oncology and Internal Medicine franchises at Shire.
Before Shire, Agustin co-founded and served as CEO/President of the cell immunotherapy start-up SQZ Biotech from 2013 to 2015. SQZ Biotech commercializes the CellSqueeze technology that was invented at MIT by Dr. Armon Sharei in the labs of biotech pioneer Professor Bob Langer and Professor Klavs Jensen. SQZ Biotech won the first prize in MassChallenge 2014 (out of 1,600+ start-ups) and it was selected as a FierceBiotech's Fierce 15 company as one of the 15 most promising biotech startups in 2015. Its technology CellSqueeze was selected as one of the 10 world changing ideas by Scientific American in 2014. SQZ Biotech signed in 2015 a $500M deal with Roche to jointly develop cancer immunotherapies.
From 2010 until 2013, Agustin worked for Novartis Vaccines as part of the Global Leadership Program with international assignments in UK, Germany, Italy and US. He was the Global Value Chain Manager for the Novartis’ meningitis vaccines portfolio ($300m in annual sales).
Agustin started his career in P&G in 2005 as an R&D engineer where he led the development of a new product in Latin America. Both final product and marketing campaign obtained best results ever when tested among target consumers. Product was later introduced in Asia and Europe. Then, he completed his MS in Chemical Engineering at MIT in 2009. Agustin has a BS in Chemical Engineering from Universidad Simon Bolivar (Caracas, Venezuela).